Clinical trial

Continuous Infusion and Intermittent Bolus Adductor Canal Block for Total Knee Arthroplasty

Name

NCKUH-11109019

Description

The investigators believed the analgesic efficacy of adductor canal block on patients receiving total knee arthroplasty. However, the analgesic effects of different delivery regimens and duration of effects are variable. The investigators hypothesize that using continuous infusion and shorter interval bolus of local anesthetics to perform adductor canal block will reduce pain scale and opioid consumption in patients receiving total knee arthroplasty compared with longer interval bolus of local anesthetics.

Trial arms

Trial start

2022-11-01

Estimated PCD

2024-06-30

Trial end

2024-09-30

Status

Recruiting

Treatment

Bupivacain

adductor canal block with 0.25% bupivacaine

Arms:

12hrs intermittent bolus, 6hrs intermittent bolus, Continuous infusion

Other names:

Marcaine

Size

Primary endpoint

Accumulated morphine consumption

In postoperative 48 hours

Eligibility criteria

Inclusion Criteria: * Adults receiving unilateral total knee arthroplasty under spinal anesthesia * American society of anesthesiologists 1-3 Exclusion Criteria: * Could not cooperate * Allergy to medicines used in the study * Chronic pain * Long term opioid use * Neuromuscular disease * Surgical complication: massive bleeding, postoperative ICU, unanticipated procedure

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 66, 'type': 'ESTIMATED'}}

Updated at

2024-04-05

1 organization

1 product

4 indications

Organization

National Cheng-Kung University Hospital

Product

Indication

Indication

Indication

Indication